🚨FTC Seeks Contempt for Shkreli's Pharma Stock Trading
Shkreli's Banned But Still Trading Pharma Stocks
TL;DR
The FTC and seven states are seeking to hold Martin Shkreli in contempt for allegedly violating his lifetime ban on trading pharmaceutical stocks and discussing the industry publicly. The ban was imposed in 2022 after Shkreli's anticompetitive scheme raised Daraprim's price from $17.50 to $750.
The FTC and seven states are taking legal action against Martin Shkreli for allegedly violating his lifetime ban on trading pharmaceutical stocks and discussing the industry publicly. The ban was imposed in 2022 after Shkreli's anticompetive scheme raised the price of Daraprim from $17.50 to $750 per pill. The states and FTC allege Shkreli has traded stocks in dozens of drug companies and discussed the industry during livestreams since the ban was imposed. They are seeking to force Shkreli to divest from all pharmaceutical companies and pay a fine equal to his profits from trading stocks. If Shkreli violates the ban again, the FTC and states are seeking to impose clear and escalating consequences, including further financial penalties and incarceration. The FTC and states are also seeking to hold Shkreli in contempt for the alleged violations.
Key Points
FTC and seven states seek contempt for Shkreli's alleged violations of lifetime ban since 2022.
Shkreli allegedly traded stocks in dozens of drug companies since ban was imposed.
FTC and states seek to force Shkreli to divest from all pharmaceutical companies and pay fine equal to profits from trading.
FTC and states seek to impose clear and escalating consequences if Shkreli violates ban again, including further financial penalties and incarceration.
FTC and states allege Shkreli discussed pharmaceutical companies at length during livestreams, evaluating stocks and predicting outcomes of pivotal clinical trials.
Why It Matters
The FTC and seven states are seeking to hold Martin Shkreli in contempt for allegedly violating his lifetime ban on trading pharmaceutical stocks and discussing the industry publicly. The ban was imposed in 2022 after Shkreli's anticompetitive scheme raised Daraprim's price from $17.50 to $750 per pill. This case highlights the ongoing scrutiny of anticompetitive practices in the pharmaceutical industry and the enforcement of lifetime bans on individuals found to have engaged in such practices.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,568 builders reading daily.